News | May 23, 2021
Bharat Parenterals receives license for Favipiravir Oral Suspension
The product patent has been already filed under fast track approval
The product patent has been already filed under fast track approval
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Subscribe To Our Newsletter & Stay Updated
